The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 6 of the 11 sources its claims cite were checked for support.
Abstract
Purpose: Randomized controlled trials with tirzepatide (TZP) displayed unprecedented glucose and body weight lowering efficacy in individuals with type 2 diabetes and/or obesity and a safety profile similar to that of glucagon-like peptide-1 receptor agonists (GLP-1RA), mainly characterized by gastrointestinal (GI) adverse events (AE). Concerns on diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were also addressed. We aimed to investigate whether the same safety issues emerged from the FDA Adverse Event Reporting System (FAERS) post-marketing surveillance database. Methods: OpenVigil 2.1-MedDRA-v24 and AERS Mine (data 2004Q1-2023Q3) were used to query the FAERS database. Reports of GI AE, diabetic retinopathy, pancreato-biliary disorders, and medullary thyroid cancer were investigated. The analysis was then filtered for age, gender, and designation as primary suspect. AE occurrence with TZP was compared to insulin, sodium-glucose cotransporter-2 inhibitors, metformin, and GLP-1RA. Results: Disproportionate reporting of GI [i.e., nausea (ROR 4.01, 95% CI 3.85–4.19)] and pancreato-biliary disorders [i.e., pancreatitis (ROR 3.63, 95% CI 3.15–4.19)], diabetic retinopathy (ROR 4.14, 95% CI 2.34–7.30), and medullary thyroid cancer (ROR 13.67, 95% CI 4.35–42.96) was detected. TZP exhibited a similar risk of GI AE and medullary thyroid cancer and a lower risk of most pancreato-biliary AE and diabetic retinopathy vs. GLP-1RA. Conclusions: TZP was associated with an increased risk of specific AE. However, its safety profile was similar to that of GLP-1RA, without increased risk of pancreato-biliary AE, diabetic retinopathy, and medullary thyroid cancer.
Overview
CoChat Summary
TL;DR
This FAERS pharmacovigilance analysis found disproportionate reporting of gastrointestinal, pancreato-biliary, diabetic retinopathy, and medullary thyroid cancer adverse events with tirzepatide. Overall, tirzepatide’s safety profile was similar to GLP-1 receptor agonists, with no increased risk of pancreatitis, diabetic retinopathy, or medullary thyroid cancer relative to that class.
Key findings
- Tirzepatide was associated with 20,409 reports related to 1,432 adverse events; 116 fulfilled Evans’ criteria, including 44 administration site/procedural complications, 20 gastrointestinal disorders, and 14 nutrition/metabolism disorders.
- Disproportionate gastrointestinal reporting included nausea (ROR 4.01, 95% CI 3.85–4.19), pancreatitis (ROR 3.63, 95% CI 3.15–4.19), impaired gastric emptying (ROR 13.3, 95% CI 10.7–16.7), and eructation (ROR 30.25, 95% CI 27.38–33.42).
- Positive signals were also detected for diabetic retinopathy (ROR 4.13, 95% CI 2.34–7.29) and medullary thyroid cancer (ROR 13.67, 95% CI 4.35–42.96), though the latter was based on only 3 events.
- Versus GLP-1RA as a class, tirzepatide showed similar risk of gastrointestinal adverse events and medullary thyroid cancer, and lower risk of most pancreato-biliary adverse events and diabetic retinopathy; it had lower risk of nausea and vomiting but greater risk of constipation, eructation, and gastrointestinal disorder.
Methods
- FAERS was queried using OpenVigil 2.1-MedDRA-v24 and AERSMine for data from 2004Q1 to 2023Q3.
- A positive disproportionality signal used Evans’ criteria: PRR ≥2, chi-squared ≥4, and ≥3 cases; reports were retrieved by MedDRA high level terms for gastrointestinal, pancreato-biliary, diabetic ophthalmic, and thyroid events.
- Analyses compared tirzepatide with all other drugs, insulin, SGLT-2 inhibitors, metformin, and GLP-1RA, with filtering for age, gender, and primary suspect designation, plus sensitivity analyses excluding concomitant insulin or GLP-1RA use.
Limitations
- The paper states that FAERS contains spontaneous reports without necessarily implying cause-effect; reporters include healthcare professionals, patients, families, representatives, and manufacturers, which can lead to duplicates and incomplete reporting, with dose, indication, gender, and age often missing.
- The paper also states that reporting may be affected by public awareness, ethnicity, geography, and timing of approval/market introduction; oral versus injectable semaglutide and daily versus weekly exenatide could often not be distinguished; and data cover approximately the first 16 months of tirzepatide availability on the U.S. market.
- Evident from the text: gender was missing in approximately 2,900 reports and age in approximately 13,000 reports, and some key signals relied on very few events (12 diabetic retinopathy events; 3 medullary thyroid cancer events), limiting precision.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
6 Valid · 0 Not valid · 6 Not checked · 43 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Gasbjerg et al. showed that endogenous GIP, and not GLP-1, also induced gallbladder relaxation.”
§ The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database > Conclusions
What the sources say
- Supportedcites [24] Gasbjerg LS, Helsted MM, Hartmann B, Sparre-Ulrich AH, Veedfald S, Stensen S et al (2020) GIP and GLP-1 receptor antagonism during a meal in healthy individuals. J Clin Endocrinol Metab 105(3):dgz175. https://doi.org/10.1210/clinem/dgz175 source
The Gallbladder volume section (pp. of Fig. 5 discussion) states that GIP(3-30)NH2 (GIP receptor blockade) raised gallbladder ejection fraction versus placebo, 'suggesting that endogenous GIP is involved in gallbladder relaxation', and that 'based on our present results, endogenous GLP-1 does not affect postprandial gallbladder volume'. The Results (Gallbladder and gastric motility) give the supporting numbers (higher maximal and bsAUC ejection fraction during GIP(3-30)NH2 vs exendin(9-39)NH2 and placebo), and the Abstract conclusion says 'only endogenous GIP affects gallbladder motility' in 12 healthy men. Both halves of the claim (GIP yes, GLP-1 no) are stated in our copy. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In line with data from the SURPASS program [3], nausea, diarrhoea, and vomiting were the most commonly reported GI AE”
§ The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database > Conclusions
What the sources say
- Supportedcites [3] Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z et al (2024) Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab 26:473–481. https://doi.org/10.1111/dom.15333 source
Section 3.2 (GI AEs and treatment discontinuation) states that nausea, diarrhoea and vomiting were the most frequently reported gastrointestinal adverse events with tirzepatide across SURPASS-1 to -5. This directly supports the cited claim. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, a higher expression of GIP receptor was found in tumor rather than normal tissue in rats and human specimens of medullary thyroid cancer”
§ The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database > Conclusions
What the sources say
- Supportedcites [31] Regazzo D, Bertazza L, Galletta E, Barollo S, Mondin A, Zovato S et al (2022) The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings. Endocr Relat Cancer 29(5):273–284. https://doi.org/10.1530/ERC-21-0258 source
The Abstract reports a high tumor-to-normal GIPR ratio in both human and rat medullary thyroid cancer. The “GIPR expression and clinical correlations” section also reports higher GIPR levels in most human tumor samples than in normal thyroid tissue. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“which are known to be associated with an increased yet small risk of gallbladder and biliary-related disorders both in patients treated for type 2 diabetes and obesity [22].”
§ The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database > Conclusions
What the sources say
- Supportedcites [22] He L, Wang J, Ping F, Yang N, Huang J, Li Y et al (2022) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 182:513–519. https://doi.org/10.1001/jamainternmed.2022.0338 source
The Discussion reports increased gallbladder or biliary disease risk in trials treating diabetes and in trials treating patients for weight loss, with higher risk in the latter. It also describes the overall absolute increase as small: 27 additional cases per 10,000 people treated per year. (LLM, conf=0.94)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Instead, HbA1c reduction was associated with increased risk of diabetic retinopathy in a meta-regression of GLP-1RA cardiovascular outcome trials [27].”
§ The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database > Conclusions
What the sources say
- Supportedcites [27] Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC (2021) HbA change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 44:290–296. https://doi.org/10.2337/dc20-1815 source
The Abstract CONCLUSIONS (Bethel et al. 2021, Diabetes Care) state verbatim that 'HbA1c reduction was significantly associated with increased retinopathy risk in meta-regression for GLP-1RA CVOTs.' The DATA SYNTHESIS and Results sections quantify this (univariate meta-regression slope = 0.77, P = 0.007; a 0.1% increase in HbA1c reduction associated with 6%, 14%, or 8% increased Ln(OR) for retinopathy at 3 months, 1 year, and overall follow-up), and the paper's Conclusions reiterate the significant meta-regression association regardless of follow-up period. The paraphrase matches the source in content, direction, method (meta-regression), and population (GLP-1RA CVOTs). (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
35 more claims
Create a free account to see all 55 claims and to verify the 5 references still open.
- It may state two separate claims as one. 13
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Notably, data from the FDA Adverse Event Reporting System indicate a lower incidence of nausea and vomiting, potentially due to GIP receptor-mediated neuronal inhibition in the area postrema [149,150], whereas constipation appears more frequent, with the underlying mechanisms yet to be fully elucidated [151].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [149]
The cited source says what the claim attributes to it.
In the citing paper
“it is noteworthy that tirzepatide exhibits a safety profile comparable to that of GLP-1 RAs.”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [149]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database > Abstract > Results
“diabetic retinopathy (ROR 4.14, 95% CI 2.34–7.30)”
§ The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database > Results > Tirzepatide vs. all other drugs
““diabetic retinopathy” (ROR 4.13, 95% CI 2.34–7.29)”
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Being an incretin-based medication, TZP inherited GLP-1RA-related concerns of diabetic retinopathy worsening, which peaked especially following the dissemination of the SUSTAIN-6 trial results with subcutaneous semaglutide [25].”
BackgroundTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802 · cited 2×
“A positive signal of disproportionality was defined as a proportional reporting ratio (PRR) of 2 or greater, chi-squared of at least 4, and 3 or more cases according to Evans’ criteria [18].”
BackgroundMethodRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Del Prato, S., Kahn, S. E., Pavo, I., Weerakkody, G. J., Yang, Z., Doupis, J., Aizenberg, D., Wynne, A. G., Riesmeyer, J. S., Heine, R. J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02188-7 · Cited by 684
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662 · cited 1×
“In the latest version of the American Diabetes Association’s Standard of Medical Care in Diabetes, TZP has been listed among the most efficacious drugs for achieving glucose-and/or body weight (BW)-lowering [1].”
BackgroundLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Self-citationDahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Cited by
Lakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Kounatidis, D. C., Vallianou, N. G., Karampela, Ι., Rebelos, E., Kouveletsou, M., Dalopoulos, V., Koufopoulos, P., Diakoumopoulou, E., Tentolouris, N., & Dalamaga, Μ. (2024) · Biomolecules · doi:10.3390/biom14111479 · Cited by 52
“The overall safety profile of tirzepatide appears to be similar to that of other GLP-1RAs, indicating that, apart from the potential increased risk of MTC, tirzepatide’s cancer risk seems aligned with established therapies in its class [336].”
Wang, M., Yang, Z., Yan, M., Shao, L., & Xiao, S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119670 · Cited by 27
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
“Tirzepatide safety profile is similar to that of GLP-1RAs, primarily causing mild/moderate gastrointestinal AEs ( nausea, diarrhea, vomiting, and constipation) during dose escalation, which decrease over time and rarely lead to treatment discontinuation [78 , 161 , 179 , 180 ].”
Metadata
- Authors
- Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F.
- Affiliations
- University of Bari Aldo Moro (IT)
- Corresponding author
- Giorgino, F.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2024-08-14
- Volume
- 47
- Issue
- 11
- Pages
- 2671-2678
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- PMC
- PMC11473560
- OpenAlex
- W4401575552
- Cited by
- 49
- References
- 35
- Citations by year
- 2026: 15 · 2025: 32 · 2024: 2
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Endocrinological Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society”.
- Università degli Studi di Bari Aldo Moro
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- tirzepatide, drug safety, adverse events, type 2 diabetes, obesity, GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, pancreatitis, diabetic retinopathy, medullary thyroid carcinoma, post-marketing surveillance, FDA Adverse Event Reporting System
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Thyroid Neoplasms, United States, United States Food and Drug Administration, Databases, Factual, Adverse Drug Reaction Reporting Systems, Carcinoma, Neuroendocrine, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. https://app.cochat.ai/papers/10.1007/s40618-024-02441-z
- The paper
- Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F. (2024). The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02441-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.